

# Orsiro<sup>®</sup> Mission DES

Even better deliverability for the outstanding Orsiro DES<sup>1</sup>



The next level of deliverability<sup>1</sup>

Better push, track and cross




Ultrathin struts<sup>2</sup>

60 μm\*




Outstanding patient outcomes<sup>3</sup>

40%  
lower TLF<sup>o</sup> vs. Xience at 36-m<sup>4</sup>




# Orsiro<sup>®</sup> Mission DES




## The next level of deliverability

Better push, track and cross<sup>1</sup>



## Outstanding patient outcomes

Clinically proven Orsiro DES<sup>4,6,7,8</sup>



TLF = Target Lesion Failure. \*ø 2.25 mm - 3.0 mm; † Based on 36-m frequentist analysis.

1. In comparison to Xience Sierra, Resolute Onyx and Synergy for bench tests on pushability, trackability and crossability, BIOTRONIK data on file; 2. As characterized with respect to strut thickness in Bangalore et al. Meta-analysis; 3. Based on investigator's interpretation of BIOFLOW-V primary endpoint result; 4. Kandzari D et al. J Am Coll Cardiol. Cardiovasc Interv. 2020, doi: 10.1016/j.jcin.2020.02.019; 5. Per investigators' interpretation of preclinical studies with Orsiro as mentioned in Cassese et al. J Thorac Dis 2018;10(2):688-692; 6. Kandzari D et al. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. Lancet. 2017 Oct 21; 7. Kandzari D, et al. BIOFLOW-V: A Prospective Randomized Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in the Treatment Of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions Science. Presentation at E SC 2017; 8. Kandzari D et al. Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents: Journal of American College of Cardiology [2018], doi: <https://doi.org/10.1016/j.jacc.2018.09.019>.

Clinical data conducted with Orsiro, Orsiro Mission's predecessor device can be used to illustrate Orsiro Mission clinical outcomes.

Orsiro and Orsiro Mission are trademarks or registered trademarks of the BIOTRONIK Group of Companies. Xience Sierra is a trademark of the Abbott Group of Companies; Synergy is a trademark of Boston Scientific; Resolute Onyx is a trademark of Medtronic Vascular Inc.